Typically less than 1 % cross reactivity against other types of Apolipoprotein was detected by ELISA against purified standards. This antibody reacts with Human Apolipoprotein A-I and has negligible cross-reactivity with Type A-II, B, C-I, C-II, C-III, E and J Apolipoproteins. Non-specific cross reaction of anti-Apolipoprotein antibodies with other Human serum proteins is negligible.
Cross-Reactivity (Details)
Species reactivity (tested):Human.
Purification
Immunoaffinity Chromatography using immobilized antigens followed by extensive cross-adsorption against other Apolipoproteins and human serum proteins to remove any unwanted specificities.
Immunogen
Apolipoprotein Type A-I was isolated from Human plasma by density gradient centrifugation followed by HPLC purification.
APOA1
Reactivity: Mouse, Rat
WB, IHC
Host: Rabbit
Polyclonal
unconjugated
Application Notes
Anti-Apolipoprotein antibodies have been used for Indirect trapping ELISA for quantitationof antigen in serum using a standard curve, for Immunoprecipitation and for Westernblotting for highly sensitive qualitative analysis. Recommended dilutions: ELISA: 1/10,000-1/20,000. Western blot: 1/5,000-1/10,000. Immunoprecipitation: 1/100. Immunohistochemistry: 1/50-1/200.
Restrictions
For Research Use only
Concentration
1.0 mg/mL (by UV absorbance at 280 nm)
Buffer
0.125 M Sodium Borate, 0.075 M Sodium Chloride, 0.005 M EDTA, pH 8.0, 0.01 % Sodium Azide, None
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Dilute only prior to immediate use. Avoid cycles of freezing and thawing.
Storage
-20 °C
Storage Comment
Store vial at -20 °C prior to opening. Centrifuge product if not completely clear after standing at room temperature. For extended storage aliquot contents and freeze at -20 °C or below.
Bernthaler, Epping, Schmitz, Deplazes, Brehm: "Molecular characterization of EmABP, an apolipoprotein A-I binding protein secreted by the Echinococcus multilocularis metacestode." in: Infection and immunity, Vol. 77, Issue 12, pp. 5564-71, (2009) (PubMed).
Apolipoprotein A I promotes cholesterol efflux from tissues to the liver for excretion. Apolipoprotein A I is the major protein component of high density lipoprotein (HDL) in the plasma. Synthesized in the liver and small intestine, it consists of two identical chains of 77 amino acids, an 18 amino acid signal peptide is removed co-translationally and a 6 amino acid propeptide is cleaved post-translationally. Apolipoprotein A I is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. Defects in the Apolipoprotein A I gene are associated with HDL deficiency and Tangier disease. The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I. The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases.Synonyms: APOA1, Apo-AI, ApoA-I, ApoAI